Janssen Research & Development, Llc

This study is testing an investigational drug called JNJ-95475939 to see if it can reduce the rash, severe itch, and pain of moderate to severe eczema (atopic dermatitis). About 256 adults with long-term, hard-to-treat eczema will receive either the drug, a placebo, or an approve…

This early-stage study is testing a new drug called bleximenib in combination with other standard leukemia treatments. It aims to find a safe and effective dose for patients with acute myeloid leukemia (AML) that has specific genetic changes. The main goals are to check for side …

This study is for people with multiple myeloma, a blood cancer, that has come back or stopped responding to prior treatments. It aims to see if a new combination of two drugs, teclistamab and daratumumab, works better and is safer than two different standard drug combinations. Ab…

This study is testing whether a single infusion of a personalized immune cell therapy (CAR-T) can better control multiple myeloma than standard long-term drug maintenance. It involves 743 adults newly diagnosed with this blood cancer who are not planning an initial stem cell tran…

This study is testing a new treatment device called TAR-200, which is placed directly into the bladder, against standard chemotherapy for people with recurring high-risk bladder cancer. It's for patients who have already tried standard BCG treatment and either cannot or choose no…

This study is testing the safety of a gene therapy injection for the second eye in people with X-linked retinitis pigmentosa, an inherited condition that causes vision loss. It is a follow-up for 24 adults and children who previously received the same treatment in their first eye…

This study is testing an injectable medication called guselkumab for adults with moderate to severe Crohn's disease. It aims to see if the drug can reduce symptoms like abdominal pain and diarrhea, and improve gut inflammation seen on a scope. Over 1,400 participants will receive…

This early-stage study is testing a new type of drug called JNJ-78278343 for men with advanced prostate cancer that has spread. The main goals are to find a safe and effective dose and to understand the side effects. The drug is designed to guide the body's own immune T-cells to …

This study is testing an investigational oral medicine called JNJ-77242113 for people with moderate to severe plaque psoriasis. It aims to see if the new drug is more effective at clearing skin and reducing symptoms than a placebo (inactive pill) and how it compares to an existin…

This study is testing whether the drug guselkumab can help children and teenagers with moderate to severe ulcerative colitis achieve and maintain remission. It involves about 112 young participants who haven't responded well to other treatments. The trial measures how well the dr…

This study compares a new two-drug combination (amivantamab plus lazertinib) against the current standard single-drug treatment (osimertinib) for people with advanced non-small cell lung cancer that has specific genetic mutations (EGFR). The goal is to see if the combination can …

This study is testing new treatment combinations for people with a high-risk form of bladder cancer that has not responded to the standard BCG therapy and who are not having their bladder surgically removed. Researchers are comparing a drug-releasing implant (TAR-200), an immunot…

This early-stage study is testing a drug called apalutamide in Chinese men whose prostate cancer has spread and no longer responds to standard hormone therapy. The main goals are to check how the drug moves through the body and to monitor its safety. Researchers will also track c…

This early-stage study is testing a new drug called JNJ-69086420 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The drug is a radioactive antibody designed to seek out and deliver radiation directly to prostate cancer …

This early-stage study is testing the safety of combining two different types of immunotherapy drugs for people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find safe dose levels and understand side effects when these drug…

This early-stage study is testing the safety and best doses of a new drug called teclistamab when it is given alongside other existing cancer drugs. It involves 140 adults with multiple myeloma, a type of blood cancer, who have tried other treatments. The main goal is to see if t…

This early-stage study is testing a new way to give the cancer drug amivantamab—as an injection under the skin instead of through an IV. It aims to find a safe and effective dose for this injection method in people with advanced solid tumors that have not responded to other treat…

This study is testing if regular injections of a drug called golimumab can help control ulcerative colitis in children and teenagers. It aims to see if the treatment can reduce symptoms and bring about remission over a year. The trial involves 84 young participants with moderate …

This early-stage study is testing several combinations of new and existing drugs for people with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find safe dose levels and check for early signs that the treatments work. The st…

This is an early-stage study to find a safe dose of a new experimental treatment called JNJ-75229414 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The treatment involves collecting a patient's own immune cells (T cells), genetically …

This study is testing a targeted drug called erdafitinib, both alone and combined with other treatments, for people with advanced bladder cancer that has spread or cannot be removed by surgery. The main goals are to find safe doses and see if these treatments can shrink tumors in…

This study aims to collect long-term safety information for children and teenagers (ages 2 to 18) who are receiving ustekinumab injections for Crohn's disease, ulcerative colitis, or psoriatic arthritis. It is an extension study for participants who benefited from the drug in a p…

This study is testing an investigational drug called JNJ-77242113 (icotrokinra) to see if it can reduce the joint pain, swelling, and skin symptoms of psoriatic arthritis. It involves 552 adults with active psoriatic arthritis who have not tried similar biologic medications befor…

This is the first study testing a new drug called talquetamab in people with advanced multiple myeloma, a type of blood cancer. The main goal is to find a safe dose and understand the drug's side effects. It is for patients whose cancer has come back or stopped responding to all …

This early-stage study is testing the safety and finding the right dose of a new personalized cell therapy called JNJ-90009530 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. Doctors will collect a patient's own immune cells, m…

This study tests whether adding the drug daratumumab to standard lenalidomide maintenance therapy helps control multiple myeloma better than lenalidomide alone. It involves 200 people who recently had a stem cell transplant for newly diagnosed multiple myeloma but still show tiny…

This program provided early access to the experimental drug teclistamab for patients with advanced multiple myeloma who had exhausted all standard treatment options. The program was designed for individuals who weren't eligible for clinical trials but had no other approved treatm…

This large study is testing whether a new oral blood thinner called milvexian works as well as the standard medication apixaban for preventing strokes in people with atrial fibrillation. Over 20,000 participants with irregular heart rhythms will take either milvexian or apixaban …

This study is testing whether adding a fourth drug called daratumumab to a standard three-drug combination works better for people newly diagnosed with multiple myeloma who aren't planning an immediate stem cell transplant. Researchers want to see if the four-drug combination hel…

This study is testing the safety and effectiveness of combining two drugs, amivantamab and cetrelimab, for people with advanced non-small cell lung cancer that has spread. The first part finds the best dose, and the second part checks how well that dose shrinks tumors in specific…

This early-stage study is testing the safety and effectiveness of new drug combinations for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. The trial is testing a pill called lazertinib alone and combined with an…

This study is testing whether different pill versions of two prostate cancer drugs (niraparib and abiraterone acetate) work similarly in the body. It involves 136 men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goal i…

This study is testing an investigational oral medicine called JNJ-77242113 for people with moderate to severe plaque psoriasis. It aims to see how well the new drug works and how safe it is compared to a placebo (inactive pill) and an approved injectable medicine called ustekinum…

This study is testing an experimental treatment called JNJ-68284528, a type of CAR-T cell therapy, for people with multiple myeloma, a cancer of plasma cells. The treatment involves genetically modifying a patient's own immune cells to target and kill cancer cells that carry a ma…

This study aimed to test if an investigational drug called nipocalimab could help control kidney damage in adults with active lupus nephritis. It was designed to work by lowering levels of harmful antibodies that attack the kidneys. The trial was a Phase 2 study that was withdraw…

This program provides continued access to the drug nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who benefited from it in a previous 28-week study. It is for participants who showed improvement in their hemoglobin levels and completed the prior study withou…

This study tested a targeted drug called erdafitinib in people with advanced bladder cancer that has spread or cannot be removed by surgery and has specific genetic changes (FGFR alterations). The main goal was to see how well the drug shrinks tumors and controls the cancer. Rese…

This is the first human study of an experimental drug called JNJ-87801493, given alongside other drugs that help the immune system fight cancer. The main goal is to find a safe dose and understand the side effects in 70 adults with B-cell non-Hodgkin lymphoma that has returned or…

This study is testing a new combination of two drugs, talquetamab and teclistamab, for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe and effective dose, check for side effects, and see how well the com…

This study is testing a new, easier-to-administer injection (a shot under the skin) for a lung cancer drug called amivantamab, which is given with another drug called lazertinib. It aims to see if this new method works as well as the standard intravenous (IV) infusion but takes l…

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy works better than chemotherapy alone for people with advanced lung cancer. It's for patients whose cancer has specific genetic changes and stopped responding to their previous…

This study is testing whether a new drug called teclistamab works better than current standard treatments for people with multiple myeloma that has come back or stopped responding to prior therapy. It will involve about 614 adults whose cancer has progressed after 1 to 3 prior tr…

This study is testing whether the drug erdafitinib can shrink tumors in adults and children with advanced solid tumors that have specific changes in a gene called FGFR. The goal is to see how well the drug works by measuring tumor shrinkage and how long the response lasts. The tr…

This is the first study in people for a new drug called Amivantamab, designed to fight advanced non-small cell lung cancer by targeting two specific proteins on cancer cells. The main goals are to find safe doses when given alone, with another drug (lazertinib), or with standard …

This study is testing two experimental drug approaches for people with muscle-invasive bladder cancer who are scheduled to have their bladder removed. One approach uses a drug-releasing device placed in the bladder plus an IV immunotherapy drug. The other uses just the IV drug al…

This large, late-stage study is testing whether an investigational drug called nipocalimab can safely reduce disease activity and ease symptoms in adults with moderate to severe Sjogren's disease. It will compare the drug against a placebo in 655 participants over 48 weeks, measu…

This is a long-term follow-up study for people who received an experimental gene therapy for X-linked retinitis pigmentosa (XLRP), a genetic disease that causes progressive vision loss. The main goals are to check the long-term safety of the treatment and to see if it continues t…

This early-stage study aims to find safe doses and check side effects when combining the investigational drug talquetamab with other approved myeloma treatments. It involves 166 participants who have multiple myeloma that has returned or stopped responding to prior therapies. The…

This study tested a new drug called teclistamab in people with multiple myeloma that had returned or stopped responding to standard treatments. The main goal was to find a safe and effective dose and see how well the drug worked at controlling the cancer. Researchers measured how…

This study is checking if a new way of making the cancer drug teclistamab works the same in the body as the current method. It involves 108 people with multiple myeloma that has come back or stopped responding to other treatments. The main goal is to see if the drug levels in the…

This program provides early access to TAR-200 for people with high-risk bladder cancer that hasn't spread into the muscle wall. It's for patients who have tried other treatments like BCG therapy but still have cancer, and who cannot or choose not to have their bladder surgically …

This early-stage study is testing a new drug called teclistamab in adults with advanced multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to understand the drug's side effects. Researchers ar…

This study is testing whether an injectable medication called guselkumab can help control symptoms and heal the gut lining in adults with moderate to severe ulcerative colitis. About 418 participants will receive either the drug or a placebo injection to see if it leads to remiss…

This study is testing two injectable drugs, ustekinumab and guselkumab, in children with active juvenile psoriatic arthritis. The goal is to see how well the drugs control the disease, reduce joint pain and swelling, and improve skin symptoms over a year. It will also measure dru…

This study is testing how well a new oral medication, called JNJ-77242113, works for people with plaque psoriasis in sensitive areas like the scalp, genitals, palms, and soles of the feet. It will involve about 311 adults and adolescents whose psoriasis hasn't responded well to c…

This large, final-stage study is testing an investigational oral medication called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. It aims to see if the new drug is more effective than a placebo (inactive pill) and how it compares to an existing approved treatme…

This study is testing whether adding a new targeted drug called amivantamab to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The main goal is to see if th…

This study is testing whether combining two existing drugs, guselkumab and golimumab, is better at controlling Crohn's disease than using either drug alone. It involves about 700 adults with moderate to severe Crohn's disease. The main goal is to see if the combination leads to f…

This study is testing different sequences of newer immunotherapy drugs for people with newly diagnosed, standard-risk multiple myeloma. Researchers want to see if these treatment combinations can lead to long-term disease control with no detectable cancer cells remaining. The stu…

This study is testing an investigational drug called M281 (nipocalimab) for adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system mistakenly attacks red blood cells. The main goal is to see if the drug can safely and durably improve hemoglobin …

This large, late-stage trial is testing whether adding a drug called niraparib to standard hormone therapy works better for controlling advanced prostate cancer that has spread. It is for men whose cancer has specific genetic changes. The main goal is to see if the combination ca…

This study is comparing two different treatment approaches for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not received prior treatment. It tests whether a combination of two newer targeted drugs (ibrutinib and venetoclax) works bet…

This is an early safety study testing a new drug called ARX517 for men with advanced prostate cancer that has spread. The study will see how safe the drug is when given alone or combined with other prostate cancer medications. Researchers will also check how the drug moves throug…

This program provides access to an investigational drug called talquetamab for people with multiple myeloma that has returned or stopped responding to all available treatments. Talquetamab is designed to help the body's own immune T-cells find and attack the cancer cells. It is o…

This study is testing whether an experimental drug called nipocalimab can help control symptoms of active idiopathic inflammatory myopathies (IIM), a group of rare autoimmune diseases that cause muscle inflammation and weakness. About 36 adults with active IIM will receive either…

This study is testing whether combining two existing drugs, guselkumab and golimumab, is more effective and safe than using either drug alone for treating moderate-to-severe ulcerative colitis. It involves about 577 adults whose condition hasn't improved enough with other advance…

This study is testing a drug called guselkumab to see if it can safely and effectively clear skin and improve quality of life for children and teenagers (ages 6 to 17) with moderate-to-severe plaque psoriasis. It's a large, late-stage trial comparing the drug against a placebo an…

This study is testing whether a new drug delivery system called TAR-200, either alone or combined with an immunotherapy drug (cetrelimab), works better than the current standard BCG treatment for high-risk bladder cancer that hasn't spread into the muscle wall. The trial involves…

This study is testing the safety and effectiveness of a combination of two immunotherapy drugs, ciltacabtagene autoleucel (a CAR-T cell therapy) and talquetamab, for people with high-risk multiple myeloma that has come back after several prior treatments. The main goal is to see …

This study is testing whether adding a drug called niraparib to a standard treatment (abiraterone acetate plus prednisone) works better than the standard treatment alone for men with advanced prostate cancer that has spread. It aims to see if the combination can delay the cancer …

This study is testing several combinations of the drug niraparib with other cancer treatments for men with metastatic castration-resistant prostate cancer (mCRPC), a serious, advanced form of the disease. The main goals are to find safe and effective doses and to see how well the…

This study is testing a combination of two drugs, amivantamab and capmatinib, for people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The first part aims to find a safe and effective dose. The second part will see how well this dose w…

This program provided early access to an investigational drug called talquetamab for patients with multiple myeloma that had stopped responding to standard treatments. It was designed for doctors to request the drug for individual patients who had exhausted other options. The pro…

This large Phase 3 study aims to find better treatments for multiple myeloma that has returned or stopped responding to previous therapies. Researchers are testing two new drug combinations against the current standard treatment in 864 participants. The main goal is to see which …

This study is testing whether the drug apalutamide can delay the rise of a prostate cancer marker (PSA) in Chinese men whose cancer has stopped responding to standard hormone therapy but hasn't spread. It will compare apalutamide against a placebo in 75 participants. The main goa…

This study is testing whether a new personalized immune cell therapy (called cilta-cel) works better than current standard drug combinations for people with multiple myeloma that has come back and is resistant to a common treatment. About 419 participants whose cancer has progres…

This early-stage study is testing whether combining two drugs, amivantamab and docetaxel, is safe and effective for people with metastatic non-small cell lung cancer that has worsened after standard chemotherapy and immunotherapy. The first part of the study aims to find the righ…

This large study is testing whether an injectable medication called guselkumab can help control symptoms and promote healing in adults with moderate-to-severe ulcerative colitis. Over 1,000 participants will receive either the drug or a placebo to see if it reduces bowel urgency,…

This study is testing whether an investigational drug called JNJ-63733657 can slow the progression of early Alzheimer's disease. The drug is an antibody designed to target and clear tau protein, one of the key abnormal proteins that builds up in the Alzheimer's brain. About 523 p…

This large, late-stage study is testing whether regular injections of a medication called guselkumab can reduce the pain, swelling, and joint damage caused by active psoriatic arthritis. It involved over 1,000 participants who still had symptoms despite standard treatments. The m…

This is the first study in people testing a new oral medication called JNJ-88998377 for patients with B-cell non-Hodgkin's lymphoma that has returned or not responded to other treatments. The main goals are to check the drug's safety and figure out the best dose for future testin…

This study is testing an oral medication called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. It aims to see how well the drug clears skin lesions, reduces symptoms like itch, and improves quality of life compared to a placebo. The trial will also monitor safe…

This study is for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder surgically removed. It compares a new treatment approach—a drug-releasing device placed in the bladder plus an immunotherapy infusion—against the current standard treatment…

This large, late-stage study is testing whether adding the drug apalutamide to standard hormone therapy, given both before and after prostate removal surgery, works better than hormone therapy alone for men with high-risk prostate cancer that hasn't spread. The main goals are to …

This is the first human study of an experimental drug called JNJ-80948543, designed to redirect a patient's own immune T-cells to attack cancer cells. It is enrolling 167 adults with advanced non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or stopped respo…

This early-stage study is testing the safety of a new two-drug combination for people with aggressive B-cell lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe and tolerable dose for future testing. Researchers will also chec…

This study is testing an injectable medication called guselkumab for adults with active psoriatic arthritis who did not get enough relief from, or could not tolerate, one prior standard biologic treatment. The main goal is to see if guselkumab is better than a placebo at reducing…

This study is testing whether an injectable medication called guselkumab can help control symptoms and heal the gut in people with moderate-to-severe Crohn's disease. It involves about 350 participants whose current treatments aren't working well enough. The main goal is to see i…

This is an early-stage study testing a new immunotherapy drug called JNJ-63723283 in people with advanced cancers that have not responded to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors in cancers like lung cancer…

This study is testing a treatment called D-VCd (daratumumab plus other drugs) for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up and damage organs, especially the heart. The main goals are to check the treatment's safety for the heart …

This study is for men with advanced prostate cancer that has spread but still responds to hormone-lowering therapy. After 6 months of successful combination treatment, participants are randomly assigned to either continue hormone therapy or take planned breaks from it. The main g…

This study is testing whether a targeted drug called erdafitinib works better than standard chemotherapy or immunotherapy for people with advanced bladder cancer that has specific genetic changes. It involves about 629 adults whose cancer has worsened after one or two prior treat…

This study is testing whether regular injections of a drug called daratumumab can delay or prevent high-risk smoldering multiple myeloma from progressing to active multiple myeloma, which requires treatment. It involves 390 participants who have the high-risk form of this precanc…

This study is testing three different medications—dexamethasone, montelukast, and methotrexate—to see if they can prevent or lessen severe allergic-like reactions that can happen during the first dose of a lung cancer drug called amivantamab. It involves 68 people with advanced n…

This study observes 545 adults with major depression who still feel significant sadness and lack of pleasure (anhedonia) despite taking common antidepressants. Researchers will track what treatments doctors try next in real-world settings and monitor how patients' symptoms and da…

This study is collecting information from people with inherited retinal diseases to better understand how these conditions progress over time. Researchers are gathering data on vision changes, genetic patterns, and how the disease affects daily life. The goal is to build knowledg…

This study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…